Jubilant Pharmova Limited has submitted its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, to the Bombay Stock Exchange and the National Stock Exchange of India. The submission marks the formal release of its first-quarter FY27 performance data, allowing investors to assess the company's operational and financial standing following the period close.

The Board of Directors approved the financial results during a meeting held on August 10, 2026. Prior to board approval, the Audit Committee reviewed the figures to ensure compliance with accounting standards. The company published the results in Financial Express (English) and Hindustan & Jansatta (Hindi) newspapers on August 11, 2026, as required by regulatory norms.

The disclosure was made pursuant to Regulation 30 and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results are also accessible via QR codes published in the newspapers and on the company’s official website. Investors can view the complete standalone and consolidated statements at www.jubilantpharmova.com .

Regulatory Compliance and Disclosure

The filing confirms that the statutory auditors have issued their review reports alongside the financial results. Naresh Kapoor, Company Secretary of Jubilant Pharmova Limited, signed the intimation letter dated August 11, 2026, requesting the exchanges to take the records on file. The submission aligns with Regulation 33 read with Regulation 47(1) of the SEBI LODR Regulations, 2015.

What This Means for Investors

The timely filing of Q1FY27 results provides transparency into Jubilant Pharmova’s early-year performance. While the specific revenue and profit figures are contained within the full financial statements linked on the company website, the approval by the Board and review by the Audit Committee signal that the financial position is verified. Shareholders can now analyze the detailed metrics to gauge the impact of market conditions on the company’s pharma operations.

Jubilant Pharmova has postponed its board meeting scheduled to consider the first quarter of FY26 financial results. The company announced on August 5, 2026, that the meeting originally set for Friday, August 7, 2026, has been rescheduled to Monday, August 10, 2026, due to unavoidable circumstances. This delay means investors will receive the Q1FY26 standalone and consolidated financial statements later than initially planned.

The postponement is governed by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board of Directors will use the rescheduled session to approve the unaudited financial results for the quarter ended June 30, 2026. No specific reason beyond "unavoidable circumstances" was provided in the intimation filed with BSE Limited and the National Stock Exchange of India Limited.

Trading Window Status

The trading window for dealing in the securities of Jubilant Pharmova remains closed for designated persons and their immediate relatives. This restriction, which began on Wednesday, July 01, 2026, will continue until Wednesday, August 12, 2026, inclusive. The closure aligns with the company's Code of Conduct framed pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended. Designated persons have been informed of the extended closure period.

Key Dates

The company secretary, Naresh Kapoor, signed the intimation on August 5, 2026. The notice was issued from the company's registered office in Noida, Uttar Pradesh. As a Jubilant Bhartia Company, Jubilant Pharmova continues to adhere to regulatory disclosure norms despite the scheduling change.